Algeta Treats First Patient In Phase II Alpharadin Trial
Algeta’s lead product Alpharadin (based on radium-223) is a highly targeted alpha-pharmaceutical under clinical evaluation, to improve survival in patients with bone metastases from advanced cancer. Its localized
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.